ECH1 inhibitors belong to a specific chemical class that has gained attention in the field of biochemical research. ECH1, also known as enoyl-CoA hydratase 1, is an enzyme involved in the fatty acid oxidation pathway, particularly in the peroxisomes of cells. ECH1 catalyzes the hydration of trans-2,3-enoyl-CoA intermediates during the breakdown of fatty acids, playing a crucial role in energy production and lipid metabolism. ECH1 inhibitors, as the name implies, are chemical compounds that specifically target and inhibit the activity of the ECH1 enzyme. These inhibitors are designed to bind to the active site of ECH1, thereby blocking its enzymatic function. By inhibiting ECH1, these compounds disrupt the normal fatty acid oxidation process and modulate cellular metabolic pathways. This class of inhibitors exhibits selectivity towards ECH1 and has the potential to modulate cellular energy homeostasis. Through their targeted inhibition, ECH1 inhibitors offer researchers a valuable tool to study the physiological and biochemical consequences of altered fatty acid metabolism. Researchers utilize ECH1 inhibitors in various in vitro and in vivo experiments to investigate the role of ECH1 in different cellular processes. By studying the effects of ECH1 inhibition, scientists can gain insights into the functional significance of this enzyme in cellular metabolism and potentially identify novel targets.
Additionally, ECH1 inhibitors contribute to a better understanding of the complex interplay between lipid metabolism and other physiological processes. The development of ECH1 inhibitors requires careful consideration of the structural features and biochemical properties of the enzyme. Structure-activity relationship studies help researchers optimize the design of these inhibitors, enhancing their potency and specificity towards ECH1. Furthermore, studies on the mechanism of action of ECH1 inhibitors aid in elucidating the molecular interactions between the inhibitors and the enzyme, facilitating the development of more potent compounds in the future. Overall, ECH1 inhibitors represent a valuable class of chemical compounds that selectively target and inhibit the activity of the ECH1 enzyme. Through their use in research, these inhibitors provide insights into the role of ECH1 in cellular metabolism and serve as important tools for understanding the complex interplay of metabolic pathways.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
rac Perhexiline Maleate | 6724-53-4 | sc-460183 | 10 mg | $188.00 | ||
Perhexiline inhibits mitochondrial carnitine palmitoyltransferase-1, indirectly affecting ECH1 by altering fatty acid uptake and beta-oxidation. | ||||||
R-(+)-Etomoxir | 124083-20-1 | sc-208201A sc-208201 | 2 mg 5 mg | $245.00 $430.00 | ||
Etomoxir inhibits carnitine palmitoyltransferase-1, reducing long-chain fatty acid entry into mitochondria, thereby indirectly influencing ECH1 activity. | ||||||
4-Hydroxy-L-phenylglycine | 32462-30-9 | sc-254680A sc-254680 | 5 g 10 g | $82.00 $109.00 | ||
4-Hydroxy-L-phenylglycine (Oxfenicine) inhibits carnitine O-palmitoyltransferase, altering fatty acid metabolism and potentially impacting ECH1 activity. | ||||||
Ranolazine | 95635-55-5 | sc-212769 | 1 g | $109.00 | 3 | |
Ranolazine inhibits fatty acid oxidation enzymes, thereby potentially modulating ECH1 activity as part of the beta-oxidation pathway. | ||||||
1-(2,3,4-Trimethoxybenzyl)piperazine | 5011-34-7 | sc-297236 | 500 mg | $374.00 | ||
1-(2,3,4-Trimethoxybenzyl)piperazine (Trimetazidine) inhibits long-chain 3-ketoacyl-CoA thiolase, which may indirectly influence ECH1 by modulating fatty acid oxidation. | ||||||
Gemfibrozil | 25812-30-0 | sc-204764 sc-204764A | 5 g 25 g | $66.00 $267.00 | 2 | |
Gemfibrozil, a lipid-regulating agent, impacts fatty acid oxidation, potentially influencing ECH1 activity. | ||||||
Clofibrate | 637-07-0 | sc-200721 | 1 g | $33.00 | ||
Clofibrate, an older lipid-lowering drug, may influence fatty acid metabolism and indirectly affect ECH1 activity. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $120.00 $326.00 $634.00 $947.00 $1259.00 | 38 | |
Rosiglitazone, a PPARγ agonist, alters lipid metabolism, which could have downstream effects on ECH1 function. | ||||||
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $55.00 $125.00 | 13 | |
Pioglitazone, another PPARγ agonist, modulates lipid metabolism, potentially impacting ECH1 activity. | ||||||